Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 99

Tesla’s Biggest FSD Problem Isn’t Technical

Questions to inspire discussion.

Marketing and Promotion.

📣 Q: What marketing strategies should Tesla employ to promote FSD? A: Tesla should invest in advertising, highlighting the cost-effectiveness of their vehicles, and invite influencers and press for a special day to meet the AI team and spread the word about FSD.

Technical Advancements.

🧠 Q: What future improvements are planned for Tesla’s FSD? A: Tesla plans to expand FSD capabilities with 10x parameters in future iterations, making it an even more valuable feature and key brand differentiator.

Safety Benefits.

Continue reading “Tesla’s Biggest FSD Problem Isn’t Technical” | >

Outbreak of Chikungunya Virus Poses Global Risk, Warns WHO

The World Health Organization warned on Tuesday a major chikungunya virus epidemic risks sweeping around the globe, calling for urgent action to prevent it.

The WHO said it was picking up exactly the same early warning signs as in a major outbreak two decades ago and wanted to prevent a repeat.

Chikungunya is a mosquito-borne viral disease that causes fever and severe joint pain, which is often debilitating. In some cases it can be deadly.

Macquarie University’s new study shows DNA ‘glue’ could help prevent and treat age related disorders

Macquarie University new study could hold the key to developing therapies for devastating age-related diseases such as motor neuron disease (MND), Alzheimer’s disease, and Parkinson’s disease.

The research at Macquarie University conducted by neurobiologist, Dr. Sina Shadfar and colleagues in the Motor Neuron Disease Research Centre, reveals a protein called protein disulphide isomerase (PDI) helps repair serious deoxyribonucleic acid (DNA) damage. This breakthrough opens new possibilities for therapies aimed at boosting the body’s ability to fix its own DNA, a process that becomes less efficient as we age.

Dr. Shadfar, Associate, Macquarie Medical School stated “Brain cells are very vulnerable. Unlike skin or blood cells, they don’t divide or renew so any damage that builds up in them stays and if the damage isn’t repaired, it can eventually lead to the death of these critical cells.”

Genetic variants linked with higher risk of developing bipolar disorder

Bipolar disorder is a mental health condition characterized by extreme mood swings, with alternating periods of depression and manic episodes. Past research suggests that bipolar disorder has a strong genetic component and is among the most heritable psychiatric disorders.

To better understand the that increase the risk of developing this mental health disorder, neuroscientists and geneticists have carried out various genome-wide association studies (GWAS). These are essentially studies aimed at identifying specific regions of the human genome that are linked with an increased risk of having bipolar disorder, also referred to as bipolar risk loci.

While earlier works have identified many of these regions, causal single nucleotide polymorphisms (SNPs) for the disorder are largely unknown. These are essentially genetic variants that primarily contribute to bipolar disorder risk, as opposed to just being mere markers of it.

Coordinated defect arrangement shown to boost superconductivity in new study

An international team of scientists, including physicists from HSE MIEM, has demonstrated that when defects within a material are arranged in a specific pattern rather than randomly, superconductivity can occur at a higher temperature and extend throughout the entire material. This discovery could help develop superconductors that operate without the need for extreme cooling.

The study has been published in Physical Review B.

Superconductivity is a state in which electric current flows through a material without any . In conventional conductors, part of the energy is converted into heat, but in superconductors, this does not occur—current flows freely and does not weaken. Today, superconductors are used in applications such as MRI machines, where superconducting coils generate strong magnetic fields.

Stowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapy

A useful review on the nucleic acid contaminants found in AAVs, how to detect such contaminants, their biological implications, and how we can minimize nucleic acid contaminants in the future through new manufacturing innovations! #biotech #genetherapy

Brimble and colleagues review nucleic acid heterogeneity of rAAV for gene therapy. Alongside the intended expression cassette, non-therapeutic DNA is present within rAAV preparations. These contaminants can be transferred and can even expressed after delivery. They discuss sources of DNA contamination in rAAV and highlight existing strategies to improve vector purity.

Bernoulli family

Originally from Antwerp, a branch of the family relocated to Basel in 1620. [ 4 ] While their origin in Antwerp is certain, proposed earlier connections with the Dutch family of Italian ancestry called Bornouilla (Bernoullie), or with the Castilian family de Bernuy (Bernoille, Bernouille), are uncertain. [ 4 ]

The first known member of the family was Leon Bernoulli (d. 1561), a doctor in Antwerp, at that time part of the Spanish Netherlands. His son, Jacob, emigrated to Frankfurt am Main in 1570 to escape from the Spanish persecution of the Protestants. Jacob’s grandson, a spice trader, also named Jacob, moved to Basel, Switzerland in 1620, and was granted citizenship in 1622. [ 4 ] His son, Niklaus Bernoulli [de] (Nicolaus, 1623–1708), Leon’s great-great-grandson, married Margarethe Schönauer.

[ edit ].

Brain Plasticity Modulator p75 Neurotrophin Receptor in Human Urine after Different Acute Brain Injuries—A Prospective Cohort Study

Acute brain injuries (ABIs) pose a substantial global burden, demanding effective prognostic indicators for outcomes. This study explores the potential of urinary p75 neurotrophin receptor (p75NTR) concentration as a prognostic biomarker, particularly in relation to unfavorable outcomes. The study involved 46 ABI patients, comprising sub-cohorts of aneurysmal subarachnoid hemorrhage, ischemic stroke, and traumatic brain injury. Furthermore, we had four healthy controls. Samples were systematically collected from patients treated at the University Hospital of Turku between 2017 and 2019, at early (1.50 ± 0.70 days) and late (9.17 ± 3.40 days) post-admission time points. Urinary p75NTR levels, measured by ELISA and normalized to creatinine, were compared against patients’ outcomes using the modified Rankin Scale (mRS). Early urine samples showed no significant p75NTR concentration difference between favorable and unfavorable mRS groups. In contrast, late samples exhibited a statistically significant increase in p75NTR concentrations in the unfavorable group (p = 0.033), demonstrating good prognostic accuracy (AUC = 70.9%, 95% CI = 53–89%, p = 0.03). Assessment of p75NTR concentration changes over time revealed no significant variation in the favorable group (p = 0.992) but a significant increase in the unfavorable group (p = 0.009). Moreover, p75NTR concentration was significantly higher in ABI patients (mean ± SD 40.49 ± 28.83–65.85 ± 35.04 ng/mg) compared to healthy controls (mean ± SD 0.54 ± 0.44 ng/mg), irrespective of sampling time or outcome (p < 0.0001). In conclusion, late urinary p75NTR concentrations emerged as a potential prognostic biomarker for ABIs, showing increased levels associated with unfavorable outcomes regardless of the specific type of brain injury. While early samples exhibited no significant differences, the observed late increases emphasize the time-dependent nature of this potential biomarker. Further validation in larger patient cohorts is crucial, highlighting the need for additional research to establish p75NTR as a reliable prognostic biomarker across various ABIs. Additionally, its potential role as a diagnostic biomarker warrants exploration.

/* */